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With the rapid spread of high-throughput technologies, 
human papillomavirus (HPV) screening triage is becoming 
increasingly important as an alternative algorithm to replace 
the cervicovaginal Pap smear. Because HPV infection does not 
always involve extensive destruction of the host microenviron-
ment, despite being a crucial causative factor in cervical cancer, 
triage algorithm any legal ground to stand on is mandatory. 
There are two main reasons for HPV screening: infection with 
certain HPV types is predictive of cervical cancer progression, 
and determining the status of HPV infection will help to 
control the spread of the virus. 
Despite the immense volume of available HPV data and the 
development of modern high-throughput technologies, there 
are two major obstacles to HPV studies: a lack of longitudinal 
studies and a lack of a gold standard for generating compara-
tive HPV data. 
An unavoidable loophole in the study of HPV exists in the 
accuracy of the atypical squamous cells of undetermined 
signi ficance (ASC-US) and cervical intraepithelial neoplasia 
(CIN) grading systems as well as in the time that it takes 
to evaluate the virus status. However, the most common, 
albeit overlooked, pitfall is the lack of a faithful gold standard 
for diagnosis, whether the diagnosis is based on biopsy or 
sequencing. A longitudinal study design based on traditional 
triage could produce new insights. 
Guo et al. [1]’s study design associated with CIN 3 is thought 
to be fair and less biased. mRNA targeting of E6/E7 takes 
greater advantage of valuable messages compared with 
DNA targeting of L1. E6/E7 expression acts as a dominant 
oncogene, with immortalization and transformation activities, 
whereas L1 merely represents a lifelong infectious sign, even if 
the infection was remote. Nonetheless, further issues regard-
ing the use of HPV mRNA and HPV DNA for diagnosis include 
the following: 
(1) mRNA+/DNA-: arbitrary; not decisive enough to be used 
regularly 
(2) mRNA-/DNA+: same clinical triage as the traditional 
algorithm
(3) mRNA-/DNA-: in case of APTIMA/Hybrid Capture 2 
(HC2), it can exclude the possibility of the other HPV geno-
types; clinical surveillance to determine whether the infection 
is active or general may be warranted
(4) mRNA+/DNA+: more specific for CIN 3+, but less specific 
for CIN 2 or lower; good predictor of CIN 3 progression (odds 
ratio of HPV 16 mRNA was 5.14; odds ratio of high-risk HPV 
[HR-HPV] mRNA was 3.37 over a 3-month period) [2]. 
In terms of the CIN concept, the CIN background switches 
to the squamous intraepithelial lesion (SIL) concept with 
the emergence of HPV as a crucial causative factor. CIN 1 is 
traditionally the period from which worse grading (i.e., CIN 2 
or 3) develops. Like CIN, SIL involves cytopathic changes that 
are restricted to the epithelial environment but are insufficient 
for neoplasia. An HPV-associated cytopathic effect alone is 
not sufficient to indicate neoplasia, because low-grade SIL 
(LSIL) is often reversible, although the virus is infectious. With 
the physical integration of the viral E6/7 genes into the host 
genome and the subsequent uncontrolled kinetic activation 
of the cell cycle, atypia in the parabasal and intermediate 
layers of the epithelium increase and high-grade SIL (HSIL) may 
develop, which is mostly irreversible, encompassing CIN 2 and 3. 
Cytology, based on cells scraped from the most superficial 
layers of the cervical epithelium, benefits from the HPV life 
cycle, because the rapidly replicating, virion-harboring koilo-
cytes colonize the upper layers of the epithelium. It is even 
more fortunate that CIN 3 reaches to the top layer. CIN 2/3 in 
the HSIL category shares identity, and very often coexists, with 
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viral replication, as does LSIL. 
LSIL cytology does not necessarily manifest as CIN 2/3 in a 
biopsy outcome, which is not surprising. CIN 2 is the most 
perplexing diagnosis, because this heterogeneous entity 
comprises viral replication and neoplastic transformation in 
the same lesion. Once transformation activity commences in 
the parabasal layer, by definition, the lesion is called a HSIL. 
Because viral replication remains active in the surface layers, 
however, as in LSIL, the final result of cytology tends to be, 
not surprisingly, LSIL. For standardization and reproducibility 
among pathologists, it might be reasonable to abandon the 
use of CIN 2 and merge CIN 2 with CIN 3. What is important is 
that LSIL (CIN 1) is discriminated from HSIL (CIN 3). 
There is a glut of inventory among the many methods to 
identify HPV, which has a small circular DNA genome. Two 
major HPV test markets are those for RNA probes that hybrid-
ize with the viral DNA genome, as in the HC2 test, and DNA 
probes that hybridize with viral DNA amplicons on a chip 
platform. Unlike traditional DNA detection, targeting the E6/
E7 mRNA aims at the crucial part of the genome. 
According to a meta-analysis comparing the accuracies of 
the Food and Drug Administration (FDA)-approved HC2 test 
(Qiagen) and the APTIMA test (Gen-Probe), the signal strength 
cutoff value is an emission light unit over 1.0, which expresses 
semiquantitatively the viral load compared with a control 
sample containing 1 pg HPV DNA/mL. 
An additional issue is coinfection involving multiple 
genotypes, which represent around 10% of HPV-infected 
cohorts. Excluding low-risk HPV (LR-HPV) and including any 
indeterminate risk type, conditions for a cumulative exhaus-
tive principle could not be identified. As multiple lesions in 
combined infections or as synergistic aggravation or bystand-
ers, combined infections currently remain poorly understood. 
For determining the mechanism and clinical implications of 
multiple infections, genotyping, rather than cocktail-based 
assays, is quite essential. To develop new triage techniques for 
cervical neoplasms and lesions associated with infection by 
multiple HPV types, well-designed longitudinal cohort studies 
with well-established gold-standard diagnoses, either after 
cloning into plasmids or by direct sequencing or biopsy, are 
also mandatory. 
LR-HPV types could be discarded from both the APTIMA and 
the HC2 tests, because they compromise the efficiencies of 
the tests, and their presence is insufficient to evoke HSIL. The 
biochemical properties of LR-HPV include weaker transforma-
tion activities, telomerase activities, and lack of a PDZ domain. 
So far, the following reasons to discriminate HR-HPV from 
LR-HPV are widely acknowledged. 
(1) The probability of viral integration into the host genome 
exceeds 50% for HPV 16 and 18, whereas integration seldom 
or never happens for LR-HPV [3].
(2) Immortalizing activity is more likely to be caused by HR-
HPV, due to high levels of CDK2 expression and low levels of 
p21/p27 expression, than by LR-HPV, due to decreased p21 
abrogation [4].
(3) Telomerase activity is higher in HR-HPV E6 [5].
(4) HR-HPV E6 contains a PDZ domain (X-S/T-V/L/I)-contain-
ing protein, forming a p53-independent target, whereas LR-
HPV E6 does not contain a PDZ domain [6].
According to the restricted FDA-approval items, future HPV 
data may be restricted to limited types of HR-HPV, ignoring 
genotypes, which raises questions about the direction of HPV 
research and whether such research will be a wearisome issue 
or an awesome issue open to new horizons beyond the classi-
cal approach to HPV in the future. 
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